Incidence, timing, and management of infections in patients receiving teclistamab for the treatment of relapsed/refractory multiple myeloma in the MajesTEC‐1 study
Ajay K. Nooka(Emory University), Niels W.C.J. van de Donk(Oncode Institute), Cesar Rodriguez(Wake Forest University), Salomon Manier(Université de Lille), Keqin Qi(Janssen (United States)), Rachel Kobos(Centre Hospitalier Universitaire de Nantes), Raluca Verona(Centre Hospitalier Universitaire de Nantes), Arnob Banerjee(Johnson & Johnson (United States)), Margaret Doyle(Janssen (Ireland)), Katherine Chastain(Janssen (United States)), Thomas G Martin(University of California, San Francisco), María‐Victoria Mateos(Hospital Clínico San Carlos)
Cited by 87
Related Papers
The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee
|Blood|2022|1.5k
Teclistamab in Relapsed or Refractory Multiple Myeloma
|New England Journal of Medicine|2022|1.2k